KRAS mutations are typically mutually exclusive, with recurrent activating mutations (KRAS (Gly 12) and KRAS (Gly 13) common in colon cancer, non-small cell lung cancer and pancreatic cancer. This evidence concerns the gene KRAS and familial pancreatic carcinoma.